insulin glargine

insulin glargine is a long-acting basal insulin analog used in the management of diabetes mellitus. It is designed to provide a steady, peakless level of insulin over approximately 24 hours, mimicking the body's natural basal insulin secretion. This medication is a cornerstone of therapy for both type 1 diabetes and type 2 diabetes, often used in conjunction with prandial insulin or other antidiabetic medication. Its development by Sanofi represented a significant advancement in diabetes management, offering improved glycemic control with a reduced risk of nocturnal hypoglycemia.

Medical uses

Insulin glargine is primarily indicated for the control of hyperglycemia in adults and children with type 1 diabetes and in adults with type 2 diabetes. It is administered as a once-daily subcutaneous injection to provide basal insulin coverage, and it is frequently combined with rapid-acting insulin analogs at mealtimes in a regimen known as basal-bolus therapy. Clinical guidelines from organizations like the American Diabetes Association recommend its use when oral hypoglycemic agents are insufficient. It is also used in the treatment of gestational diabetes under specialist supervision and is a key component in insulin pump therapy for some patients.

Adverse effects

The most common adverse effect is hypoglycemia, which can range from mild to severe, including episodes of nocturnal hypoglycemia. Injection site reactions, such as lipodystrophy, pruritus, and erythema, are also frequently reported. Other potential effects include peripheral edema, weight gain, and allergic reactions. Rare but serious risks include hypokalemia and severe anaphylaxis. The U.S. Food and Drug Administration monitors reports of potential associations with cardiovascular events, though large studies like ORIGIN trial have provided extensive safety data.

Pharmacology

Insulin glargine is a recombinant DNA human insulin analog where the asparagine at position A21 is replaced by glycine and two arginine residues are added to the C-terminus of the B-chain. These modifications shift the isoelectric point, making the solution soluble at an acidic pH but causing it to form microprecipitates in the neutral subcutaneous tissue. This results in a slow, predictable release into the systemic circulation. It acts by binding to the insulin receptor on cells, facilitating glucose uptake in skeletal muscle and adipose tissue, and inhibiting hepatic glucose production. Its pharmacokinetics show a flat, prolonged action profile with no pronounced peak.

History

The development of insulin glargine was pioneered by researchers at Hoechst AG, which later became part of Aventis and ultimately Sanofi. It was created to address the limitations of NPH insulin, such as its pronounced peak and variable duration. The drug received approval from the European Medicines Agency in 2000 and from the U.S. Food and Drug Administration later that same year under the brand name Lantus. Subsequent formulations, including a more concentrated version marketed as Toujeo, were later introduced. The ORIGIN trial, a major outcomes study, investigated its long-term cardiovascular effects.

Society and culture

Marketed globally under brand names like Lantus, Toujeo, and Basaglar, insulin glargine has been a subject of significant discussion regarding drug pricing and healthcare access. Its patent expiration led to the introduction of biosimilar versions, such as Semglee, increasing market competition. The high cost of insulin analogs has been scrutinized by policymakers, including the U.S. Congress, and advocacy groups like the American Diabetes Association. Its role is featured in treatment guidelines from the International Diabetes Federation and is a frequent topic in medical education and continuing medical education programs worldwide.

Category:Antidiabetic drugs Category:Insulins Category:World Health Organization essential medicines